Bruker Corporation has announced significant advancements in mass spectrometry technology at the 73rd American Society for Mass Spectrometry (ASMS) Conference. The company unveiled the timsMetabo™ platform, which offers high-sensitivity analysis for small molecules, specifically targeting PFAS and environmental contaminants. Additionally, Bruker introduced the integration of RECIPE's ClinMass® and ClinDART® assay kits with its EVOQ® DART-TQ⁺ system, aimed at improving therapeutic drug monitoring (TDM) and drugs of abuse (DoA) analysis. These innovations are expected to enhance laboratory productivity by enabling high-throughput, chromatography-free workflows. Bruker plans to further develop solutions for forensic toxicology and emerging contaminants, underlining its commitment to addressing real-world analytical challenges.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.